Juno Therapeutics will resume its Phase II ROCKET clinical
trial of its acute lymphoblastic leukemia candidate JCAR015 following the FDA's lifting of a partial clinical hold imposed last week following the deaths of three patients.
However, genetic mutations in a gene called mixed lineage leukemia, or MLL, lead to an aggressive subtype of B - ALL known as MLL - rearranged, which is the most common type
of acute lymphoblastic leukemia in infants.
Juno Therapeutics is seeking to change the protocol for the Phase II ROCKET clinical trial
of its acute lymphoblastic leukemia candidate JCAR015, which the FDA has placed on clinical hold following the deaths of three patients, two of them last week.
A University of Colorado Cancer Center study published today in the journal Nature Genetics describes a newly - discovered, heritable genetic
cause of acute lymphoblastic leukemia (ALL), namely mutation of the gene ETV6.
An international group of researchers led by Prof. Jan Cools of the VIB - KU Leuven Center for Cancer Biology have made a breakthrough in understanding the
development of acute lymphoblastic leukemia, an aggressive cancer of the blood.
«The data show that aberrant epigenetic gene programming can now be considered a
hallmark of acute lymphoblastic leukemia, occurring in all patients regardless of the presence of genetic mutations,» Melnick said.
A group of researchers at the Baylor College of Medicine has published the results of a study in the journal PLoS ONE demonstrating that a concentrated form of the compound sulforaphane found in broccoli and other cruciferous vegetables has been shown to reduce the
number of acute lymphoblastic leukemia cells in a lab setting.
The changes included reductions in the use and dose of radiation therapy and chemotherapy drugs called anthracyclines for
treatment of acute lymphoblastic leukemia (ALL), Hodgkin lymphoma and Wilms tumor, a cancer of the kidneys.